Related Experiment Videos
Immuno-stimulatory effect of levamisole in borderline leprosy cases
Indian Journal of Leprosy
|January 1, 1985
Abstract:
Eleven cases of borderline-borderline leprosy were subjected to levamisole therapy for 3 months. Levamisole was given 150 mg/day on three consecutive days every fortnight along with dapsone (DDS). Immuno-stimulation was assessed by lepromin test using Lepromin-A supplied by W.H.O. containing 4.0 X 10(7) bacilli per milli litre. It was found that there was statistically significant change in lepromin reaction after levamisole therapy.
Insights
Levamisole therapy improved immune response in leprosy patients. This study shows a significant change in lepromin reactions after 3 months of levamisole and dapsone treatment for borderline-borderline leprosy.
Area of Science:
- Immunology
- Infectious Diseases
- Dermatology
Background:
- Leprosy, specifically borderline-borderline leprosy, presents complex immunological challenges.
- Standard treatments like dapsone (DDS) may benefit from immunomodulatory adjuncts.
Purpose of the Study:
- To evaluate the immunomodulatory effect of levamisole in patients with borderline-borderline leprosy.
- To assess changes in cellular immune response as measured by the lepromin test.
Main Methods:
- Eleven patients with borderline-borderline leprosy received levamisole (150 mg/day for 3 consecutive days every fortnight) combined with dapsone (DDS).
- Treatment duration was 3 months.
- Immune stimulation was assessed using the World Health Organization (WHO) Lepromin-A test.
Main Results:
- A statistically significant change in lepromin reaction was observed after the 3-month levamisole therapy.
- This indicates a measurable impact on the cellular immune response.
Conclusions:
- Levamisole, when used as an adjunct to dapsone, demonstrates immunomodulatory potential in borderline-borderline leprosy.
- Further research is warranted to explore levamisole's role in enhancing leprosy treatment outcomes.